Immune-signatures associated with ocrelizumab treatment in early relapsing-remitting multiple sclerosis: new data on T cell function and pro/anti-inflammatory monocytes of the 12-month interim analysis from the MA30143 phase IIIb (ENSEMBLE) substudy